Pfizer Reports Strong Financial Results, Indicating Positive Growth Trajectory in May 2025

Pfizer, a prominent player in the Pharmaceuticals & Biotechnology industry, has reported its financial results for the quarter ending March 2025. The results, declared on May 19, 2025, indicate a notable shift in the company's evaluation, with a revision in its score reflecting recent performance.
The financial data reveals that Pfizer achieved its highest quarterly net sales in the last five quarters, totaling Rs 591.91 crore. This positive trend is mirrored in the operating profit, which also reached a peak of Rs 227.50 crore, showcasing enhanced operational efficiency with an operating profit margin of 38.43%.

Additionally, the profit before tax (PBT) stood at Rs 208.41 crore, marking a significant growth compared to the previous four quarters. The profit after tax (PAT) also reached a new high of Rs 196.63 crore, demonstrating a robust increase over the same period. Furthermore, earnings per share (EPS) hit Rs 72.34, indicating improved profitability for shareholders.

Overall, these results suggest a favorable trajectory for Pfizer, leading to adjustments in its evaluation metrics.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.